The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer

Nikhil Vasdev, Jose Dominguez-Escrig, Edgar Paez, Mark I Johnson, Garrett C Durkan, Andrew C Thorpe, Nikhil Vasdev, Jose Dominguez-Escrig, Edgar Paez, Mark I Johnson, Garrett C Durkan, Andrew C Thorpe

Abstract

Aim: To evaluate the impact of early re-resection on the incidence of tumour recurrence and progression in patients with pT1 high-grade non-muscle invasive bladder cancer (HG-NMIBC).

Patients and methods: From 2001 to 2008, 486 consecutive patients were diagnosed with pT1 HG-NMIBC. Data were collected retrospectively which included patient demographics, histological parameters including the presence of detrusor muscle at initial TUR and at re-resection, adjuvant intravesical therapy, and recurrence and progression rates. Early re-resection was performed within six weeks of initial TUR. Patients comprised those who underwent an early re-resection (Group A, n = 172) and those who did not (Group B, n = 314).

Results: At initial TUR, detrusor muscle was present in 61% (n = 105) of patients in Group A and 76% (n = 240) of patients in Group B. At early re-resection, detrusor muscle was present in 77.9% of cases. A residual tumour was present in 54.6% of re-resected cases. The overall incidence of tumour recurrence was 35% and 42% in Groups A and B, respectively. During follow-up, there was a significantly higher rate of tumour stage progression in patients who did not undergo early re-resection (Group B 14.4% vs. Group A 3.3%, P < 0.05).

Conclusions: Early re-resection facilitates accurate staging and clearance of residual disease. Subsequent rates of tumour stage progression are significantly improved. We advocate early re-resection for all patients with HG-NMIBC.

References

    1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts and Figs 2007. Atlanta, GA: American Cancer Society; 2007.
    1. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006;97:1194–8. doi: 10.1111/j.1464-410X.2006.06145.x.
    1. Lachand AT, Texier J, Texier P. Surveillance and prognosis of “Ta” superficial tumors of the bladder. Homogeneous series of 138 cases followed for 1 to 18 years. Prog Urol. 2001;11:466–71.
    1. Lachand AT, Texier J, Texier P. Surveillance and prognosis of “T1” superficial tumors of the bladder. Homogeneous series of 88 cases followed for 1 to 22 years. Prog Urol. 2001;11:472–7.
    1. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170:433–7. doi: 10.1097/01.ju.0000070437.14275.e0.
    1. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175:1641–4. doi: 10.1016/S0022-5347(05)01002-5.
    1. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol. 2001;165:808–10. doi: 10.1016/S0022-5347(05)66532-9.
    1. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523–31. doi: 10.1016/S0302-2838(02)00068-4.
    1. Divrik T, Yildirim U, Eroglu AS, Zorlu F, Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol. 2006;175:1258–61. doi: 10.1016/S0022-5347(05)00689-0.
    1. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol. 2010;58:185–90. doi: 10.1016/j.eururo.2010.03.007.
    1. Dwivedi US, Kumar A, Das SK, Trivedi S, Kumar M, Sunder S, Singh PB. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy. Urol Oncol. 2009;27:514–9. doi: 10.1016/j.urolonc.2008.04.015.
    1. Han KS, Joung JY, Cho KS, Seo HK, Chung J, Park WS, Lee KH. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol. 2008;22:2699–704. doi: 10.1089/end.2008.0281.
    1. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162:74–6. doi: 10.1097/00005392-199907000-00018.
    1. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol. 2004;45:539–46. doi: 10.1016/j.eururo.2003.12.016.
    1. Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991;146:316–8.
    1. Mersdorf A, Brauers A, Wolff JM, Schneider V, Jakse G. Second transurethral resecton for superficial bladder cancer: a must? J Urol. 1998;159:143.
    1. Rigaud J, Karam G, Braud G, Glemain P, Buzelin JM, Bouchot O. T1 bladder tumors: value of a second endoscopic resection. Prog Urol. 2002;12:27–30.
    1. Schips L, Augustin H, Zigeuner R, Trummer H, Pummer K, Hubmer G. Is a second transurethral resection justified in patients with newly diagnosed bladder cancer? Eur Urol. 2000;37:111.
    1. Schips L, Augustin H, Zigeuner RE, Galle G, Habermann H, Trummer H, Pummer K, Hubmer G. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology. 2002;59:220–3. doi: 10.1016/S0090-4295(01)01522-9.
    1. Schwaibold H, Treiber U, Kubler H, Leyh H, Hartung R. Significance of second transurethral resection for T1 bladder cancer. Eur Urol. 2000;37:111.
    1. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97:1199–201. doi: 10.1111/j.1464-410X.2006.06144.x.
    1. Vogeli TA, Grimm M, Ackermann R. Prospective study for quality control of transurethral resection of bladder tumors by routine second transurethral resection. J Urol. 1988;159:143.
    1. Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int. 2004;72:99–102. doi: 10.1159/000075961.
    1. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol. 2003;43:241–5. doi: 10.1016/S0302-2838(03)00040-X.
    1. Vasdev N, McKie C, Dominguez-escrig JL, El-Sherif A, Johnson MI, Rix DA, Durkan GC, Thorpe AC. The role of early re-resection in pTaG3 transitional cell carcinoma of bladder. Br J Med Surg Urol. 2011;4(4):158–65. doi: 10.1016/j.bjmsu.2011.01.001.
    1. Engelhardt PF, Simak R, Daha LK, Plas E, Pflüger H. Die Wertigkeit der 2nd look transurethralen Elektrosektion beim oberflachlichen Blasenkarzinom. Akt Urol. 2001;32:173–7. doi: 10.1055/s-2001-15848.
    1. Köhrmann KU, Woeste M, Kappes J, Rassweiler J, Alken P. Der Wert der transurethralen Nachresektion beim oberflachlichen Harnblasenkarzinom. Akt Urol. 1994;25:208–13. doi: 10.1055/s-2008-1058226.
    1. Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 6th. New York: Wiley-Liss; 2002. pp. 199–202.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir